These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
796 related articles for article (PubMed ID: 25965361)
1. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Eggermont AM; Maio M; Robert C Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361 [TBL] [Abstract][Full Text] [Related]
2. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
3. Combination Immunotherapy Development in Melanoma. Eggermont AMM; Crittenden M; Wargo J Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333 [TBL] [Abstract][Full Text] [Related]
4. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415 [TBL] [Abstract][Full Text] [Related]
7. New drugs in melanoma: it's a whole new world. Eggermont AM; Robert C Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade in patients with melanoma metastatic to the brain. Di Giacomo AM; Margolin K Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364 [TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 therapy in melanoma. Homet Moreno B; Parisi G; Robert L; Ribas A Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365 [TBL] [Abstract][Full Text] [Related]
11. [Understanding current therapies in metastatic melanoma]. Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962 [TBL] [Abstract][Full Text] [Related]
12. Anti-CTLA-4 antibody adjuvant therapy in melanoma. Eggermont AM; Testori A; Maio M; Robert C Semin Oncol; 2010 Oct; 37(5):455-9. PubMed ID: 21074060 [TBL] [Abstract][Full Text] [Related]
13. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in melanoma: Recent advances and future directions. Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635 [TBL] [Abstract][Full Text] [Related]
15. The role of nivolumab in melanoma. Gomes F; Serra-Bellver P; Lorigan P Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782 [TBL] [Abstract][Full Text] [Related]
16. The ipilimumab lesson in melanoma: achieving long-term survival. Delyon J; Maio M; Lebbé C Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357 [TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Hersey P; Gowrishankar K Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788 [TBL] [Abstract][Full Text] [Related]